| Item Type | Name |
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Protease Inhibitors
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Cyclooxygenase 2 Inhibitors
|
|
Concept
|
Topoisomerase I Inhibitors
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Academic Article
|
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
|
|
Academic Article
|
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
|
|
Academic Article
|
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
|
|
Academic Article
|
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
|
|
Academic Article
|
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
|
|
Academic Article
|
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
|
|
Academic Article
|
Irinogenetics: what is the right star?
|
|
Academic Article
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
|
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
|
Academic Article
|
Protein kinase C beta in malignant pleural mesothelioma.
|
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
|
Academic Article
|
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
|
|
Academic Article
|
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
|
|
Academic Article
|
Ethnic differences and functional analysis of MET mutations in lung cancer.
|
|
Academic Article
|
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
|
|
Academic Article
|
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
|
|
Academic Article
|
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
|
|
Academic Article
|
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
|
|
Academic Article
|
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
|
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
|
Academic Article
|
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
|
|
Academic Article
|
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
|
|
Academic Article
|
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
|
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
|
Academic Article
|
Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.
|
|
Academic Article
|
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
|
|
Academic Article
|
New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer.
|
|
Academic Article
|
Angiogenesis inhibition in the treatment of lung cancer.
|
|
Academic Article
|
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
|
|
Academic Article
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
|
Academic Article
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
|
Academic Article
|
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
|
|
Academic Article
|
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
|
|
Academic Article
|
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
|
|
Academic Article
|
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
|
|
Academic Article
|
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
|
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
|
Concept
|
Matrix Metalloproteinase Inhibitors
|